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Abstract 
Inherited thrombocytopenias (IT) are a heterogeneous group of diseases caused by at 
least 26 different genes. At present, these genes account for approximately 50% of 
cases, suggesting that novel genes have yet to be identified for a comprehensive 
understanding of platelet biogenesis defects. This review provides an update of ITs 
focusing on the molecular basis and potential pathogenic mechanisms affecting 
megakaryopoiesis and platelet production. 
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Introduction 
Inherited thrombocytopenias (IT) are a heterogeneous group of diseases characterized 
by variable expressivity of the bleeding tendency due to low platelet count sometimes 
associated with platelet dysfunction. Platelets, whose normal count ranges between 
150 and 450x10
9
/L, are quiescent when they circulate in the blood stream. After 
vessel injury they bind to the subendothelial von Willebrand factor, releasing the 
content of their granules, which draws other platelets to the site to prevent blood loss. 
Thanks to the application of next generation sequencing, novel ITs have recently been 
described, improving our knowledge not only in definition of the clinical spectrum of 
ITs but also into the molecular mechanisms of platelet biogenesis. At present, 
mutations in more than 20 different genes are known to cause ITs. However, these 
genes account for approximately 50% of the IT patients, suggesting that novel forms 
are still to be characterized (1). The IT genes play a variety of roles in 
megakaryopoiesis and platelet production though their function is often unclear and 
needs to be further investigated. Although information is limited in many cases, this 
review aims at classifying ITs according to our knowledge of their molecular 
mechanisms. After a brief description of megakaryopoiesis and platelet release, the 
diseases are subdivided into three major groups, based on which phase of the cellular 
process leading to platelet production is defective (Fig. 1). 
 
Megakaryopoiesis and platelet production 
Platelets are generated from megakaryocytes (Mk) through a complex process that 
requires thrombopoietin (THPO) (Fig. 1). The binding of THPO to its receptor (MPL) 
results in dimerization of MPL and activation of a signaling cascade for commitment 
of hematopoietic stem cells to Mks and other blood cells (2). Although it is a 
continuous process, megakaryopoiesis could be distinguished into two phases, 
proliferation and maturation. During the early phase committed cells proliferate and 
differentiate into immature Mks. Then, the immature cells undergo endomitosis, a 
hallmark of the maturation process, accumulating DNA up to a content of 128n. They 
produce large amounts of mRNA and proteins, including those for platelet 
adhesiveness, hemostasis and wound healing that are stored into α-granules, the most 
abundant organelles in platelets (3). 
Mature Mks migrate from the osteoblastic to the vascular niche of the bone marrow, 
where they form pseudopodia (Fig. 1). Pseudopodia elongate and branch generating 
long processes (proplatelets) extending into the sinusoidal blood vessels (4). 
Proplatelet formation is mainly driven by apoptotic pathways and remodeling of the 
microtubule cytoskeleton (5, 6). Microtubules of α/β-tubulin dimers organize into 
thick bundles where the pseudopodia originate and elongate forming increasingly 
narrower bundles as the proplatelets extend. At the distal end, the microtubule bundle 
loops and generates a teardrop-shaped structure that is released into the blood stream 
as a preplatelet, an intermediate form then converted into single platelets (6). 
Proliferation and maturation of Mks, or proplatelet formation could be affected by 
disease-causing variants in genes controlling the different phases of platelet 
biogenesis (Fig.1). When the early phases of megakaryopoiesis are defective, 
proliferation of the committed cells is impaired resulting in absence or reduction of 
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Mks in the bone marrow. In case of defective maturation, Mks are normal or even 
increased in number but immature, being small and with a hypolobulated nucleus 
and/or reduced α-granules. Thrombocytopenia associated with normal Mk production 
has been considered a hallmark of defective proplatelet formation, though platelet 
removal might also contribute to thrombocytopenia. 
 
Defects in the early phase of megakaryopoiesis: lack or reduction of Mk 
production 
Due to the key role of the THPO/MPL pathway, loss-of-function variants in the MPL 
gene cause congenital amegakaryocytic thrombocytopenia (CAMT; OMIM 604498). 
CAMT is a severe autosomal recessive disease with a high risk of life-threatening 
hemorrhages that evolves to bone marrow aplasia (7). Many different pathogenic 
variants of MPL have been identified in homozygous or heterozygous compound 
subjects (7-9). Consistent with genotype/phenotype correlations, complete loss of the 
MPL function is associated with permanently low platelet counts, while in the case of 
residual activity there is transient improvement of thrombocytopenia within the first 
year of life (7). The MPL variants explain approximately 60% of amegakaryocytic 
individuals, suggesting genetic heterogeneity of CAMT (7). 
On the contrary, heterozygous gain-of-function variants of the THPO gene are 
associated with increased platelet production (10, 11). However, at least one loss-of-
function variant (p.R38C), which is likely to reduce the binding affinity of THPO for 
MPL, has been identified in a large Micronesian family (12). Whereas the 
heterozygous individuals have mild thrombocytopenia, the homozygous ones develop 
aplastic anemia, supporting the role of the THPO/MPL pathway in the hematopoietic 
stem cell regulation. Similarly, microdeletions at 3q26.33-3q27.2 containing THPO 
are associated with mild thrombocytopenia (13, 14), suggesting that platelet 
production might be sensitive to THPO dosage. 
There are at least another two ITs that could be included in this group, radioulnar 
synostosis with amegakaryocytic thrombocytopenia (RUSAT; OMIM 605432) and 
thrombocytopenia-absent radius syndrome (TAR; OMIM 274000), both associated 
with skeletal defects of the radius. Thrombocytopenia is usually severe due to absence 
or reduction of Mks in the bone marrow but, whereas it might evolve into aplastic 
anemia in RUSAT, the platelet count tends to increase during life in TAR individuals. 
RUSAT is a rare autosomal dominant IT that can be caused by variants of the 
HOXA11 gene (15). HOXA11 encodes for a homeobox protein that regulates gene 
expression, morphogenesis, and differentiation, whose role in hemopoiesis is not 
clear. 
TAR was first associated with a microdeletion on chromosome 1q21.1 (16), which 
was, however, present in many healthy family members. Thanks to next generation 
strategies, one of the two low-frequency SNPs (rs139428292 in 5’UTR and 
rs201779890 in intron 1) of the hemizygous RBM8A gene was identified in the 
affected individuals (17). Identification of compound heterozygotes carrying one null 
allele and one of the two SNPs on the other allele further supported the role of 
RBM8A in TAR. Since RBM8A is down regulated in TAR platelets, the two SNPs are 
likely to be hypomorphic variants affecting regulatory regions. RBM8A encodes for 
RNA-binding protein 8A, a subunit of the exon-junction complex that is required for 
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mRNA metabolism processes, such as splicing, mRNA export, and nonsense-
mediated mRNA decay. However, the role of RBM8A in megakaryopoieis remains 
unknown, though its low expression is likely to affect mRNA processing of 
components of the THPO/MPL pathway, as platelets of TAR individuals do not 
respond to recombinant THPO (18). 
 
Defective maturation: production of immature Mks  
Defects of megakaryopoiesis may also appear later, during the maturation of Mks. 
Interestingly, most of the ITs with defects in this phase are associated with alterations 
of genes encoding for transcription factors. These constitute a complex network of 
numerous elements, such as RUNX1, a master regulator of hematopoiesis, FLI1 
regulating divergence of bipotential megakaryocytic/erythroid progenitors into 
platelets, and GATA1, FOG1, or GFI1B, which play a role in megakaryocytic and 
erythroid lineages. 
Three of the ITs included in this group are characterized by an increased risk of 
developing hematological malignancies, including the familial platelet disorder with 
propensity to acute myelogenous leukemia (FPD-AML; OMIM 601399), which is 
caused by mutations in RUNX1. In addition to moderate thrombocytopenia, 
individuals with FPD-AML are at risk of developing myelodysplastic syndromes or 
acute myeloid leukemia (19). In PFD-AML, Mks are small but increased in number 
and platelets have a low content of α-granules. RUNX1 interacts with subunit β of the 
core-binding factor (CBF-β), which protects it from degradation and enhances its 
affinity for DNA (20). Different mutations have a haploinsufficiency effect, though a 
few missense variants act in a dominant-negative manner (21). Retaining the ability to 
interact with CBF-β and/or the DNA binding activity, the dominant-negative products 
compete with the wild-type protein leading to a higher risk for hematological 
malignancies.  
RUNX1 down-regulates the expression of ANKRD26, a gene associated with 
ANKRD26-related thrombocytopenia (ANKRD26-RT or THC2; OMIM 188000). In 
this autosomal dominant IT, Mks are increased in number with evidence of 
dysmegakaryopoiesis due to small Mks with hypolobulated nuclei and reduced α-
granule content (22). Moreover, Mks and platelets have particulate cytoplasmic 
structures (PaCS), consisting of accumulation of proteasome complexes and 
polyubiquitinated proteins that might contribute to thrombocytopenia (23). As in 
FPD-AML, patients are at risk of developing hematological malignancies, in 
particular acute myeloid leukemia (22, 24). Variants associated with the disease are 
all localized in a short stretch of nucleotides from c.-134G to c.-113A of the 5’ UTR 
(22, 25, 26). Since the molecular genetic testing of ANKRD26 is usually directed only 
to the 5’UTR, it is likely that alterations of the coding region are underestimated. 
Indeed, one germline and one somatic amino acid substitution have been identified in 
a thrombocytopenic family and in an individual with acute myeloid leukemia, 
respectively (27, 28). 
Data from in vitro assays suggests that the ANKRD26 variants, as the SNPs in 
RBM8A, alter the mechanisms controlling gene expression (25). Indeed, RUNX1 
binds the 5’UTR stretch inhibiting the ANKRD26 transcription progressively along 
the Mk differentiation up to almost the complete absence of mRNA in mature cells 
(26). Instead, when the 5’ UTR is mutated, the expression of ANKRD26 persists, 
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resulting in constitutive activation of the TPO/MPL signaling, mainly of the 
MAPK/ERK1/2 pathway. Since the inhibition of this pathway is fundamental for 
proplatelet formation, patients’ Mks have profound defects in proplatelet formation 
(23). 
ETV6 is another tumor suppressor, whose somatic alterations have been associated 
with leukemia or myelodysplastic syndromes (29). It is a transcription factor of the 
ETS family characterized – as the other members - by the pointed (PNT) domain, 
which is involved in dimerization and interaction with other factors such as FLI1, a 
central region regulating the inhibitory effect, and the DNA-binding domain (ETS) 
(30). Four different germline missense variants affecting the central or the ETS 
domain have recently been identified in families with thrombocytopenia and different 
hematological malignancies (ETV6-related thrombocytopenia; ETV6-RT) (31, 32). 
Consistent with a maturation defect, Mks are small and hypolobulated in ETV6-RT 
individuals. The mutations prevent ETV6 from migrating into the nucleus and 
transcriptionally repressing target genes. Although knockout mice are embryonic 
lethal, the role of ETV6 during hematopoiesis has been established in 
megakaryocytic/erythroid conditional animal models. They have thrombocytopenia 
and an increased number of immature Mks, implicating the importance of ETV6 in 
platelet biogenesis (33, 34). 
Like ETV6, FLI1 is a member of the ETS family and cooperates with RUNX1 during 
megakaryopoiesis (35). FLI1 is localized at 11q24.3, a chromosomal region that is 
deleted in Jacobsen syndrome (JBS; OMIM 147791). In addition to several 
dysmorphic features due to hemizygosity of different genes, JBS individuals have 
thrombocytopenia (also known as Paris-Trousseau syndrome – TCPT; OMIM 
188025) (36). In TCPT, Mks are small with low ploidy level and have major defects 
in proplatelet production; platelets are increased in size with giant α-granules (37). 
The hypothesis that haploinsufficiency of FLI1 is responsible for thrombocytopenia is 
supported by observations that overexpression of FLI1 restores megakaryopoiesis in 
hemizygous hematopoietic staminal cells (30). Moreover, point alterations have 
recently been identified in a few families with excessive bleeding (38). In these cases, 
platelets are not only reduced in number but have also defective aggregation. Of note, 
like RUNX1, FLI1 binds to the 5’ UTR region of ANKRD26 in a consensus sequence 
close to the mutated stretch and synergistically has an inhibitory effect on the gene 
transcription (22, 26). 
GATA1 is another transcription factor that together with RUNX1 and FLI1 regulates 
megakaryopoiesis (39). It controls biogenesis of both erythrocytes and platelets, 
which originate from a common bipotential megakaryocytic/erythroid progenitor. 
Indeed, variants of GATA1 cause an X-linked thrombocytopenia with either 
dyserythropoietic anemia (XLTDA; OMIM 300367) or β-thalassemia (XLTT; OMIM 
314050) (40). In these GATA1-related diseases (GATA1-RD), maturation of Mks is 
severely compromised and platelets are large with reduced α-granule content. 
GATA1 consists of one N-terminal (Nf) and one C-terminal (Cf) zinc finger domain. 
The different GATA1 variants affect the Nf domain, which interacts with FOG1 
(friend of GATA1) with one surface and binds to DNA with the opposite surface. 
Amino acid substitutions p.V205M, p.G208R/S, and p.D218G/Y impair the 
GATA1/FOG1 interaction and are associated with dyserythropoietic anemia. 
Affecting the DNA binding surface, the sixth p.R216Q substitution is typical of 
GATA1-RD individuals with β-thalassemia (41). However, the GATA1 variants do not 
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explain completely the patients’ phenotype (42), suggesting that further investigations 
are needed to better understand the pathophysiological mechanisms underlying the 
hematological features.  
Another transcription factor governing the maturation of Mks and erythroid cells is 
the GFI1B repressor. Two null variants affecting the DNA binding domain prevent 
repression of target genes (43, 44). They exert a dominant negative effect when co-
expressed with the wild type form, consistent with the Gfi1b+/- mouse, which has no 
blood abnormalities (45). Individuals carrying the GFI1B mutations have dysmorphic 
Mks, moderate thrombocytopenia with large platelets showing variable reduction, 
including absence in some cells, of the α-granule content, and subtle red cell 
phenotype characterized by anisopoikilocytosis (43, 44). The phenotype of the 
GFI1B-related thrombocytopenia (GFI1B-RT; OMIM 187900) is similar to that of 
individuals with GATA1-RD, suggesting that GFI1B and GATA1 cooperate in the 
same cascade of events controlling the expression of genes essential for platelet and 
red cell formation. As for the other mutated transcription factors, identification of the 
target genes would provide relevant insight into the molecular pathways that are 
important for megakaryopoiesis and platelet production. 
As mentioned, platelet α-granules are variably reduced in platelets from different ITs, 
including ANKRD26-RT, GATA1-RD, and GFI1B-RT (43). On the contrary, platelets 
are typically gray in gray platelet syndrome (GPS; OMIM 139090) due to the 
complete lack of α-granules. In addition to thrombocytopenia with large platelets, 
GPS individuals have additional features, such as splenomegaly, myelofibrosis and 
increased serum B12. Although GPS was a well-known disease, the gene (NBEAL2) 
was identified only thanks to next generation sequencing approaches (46-48). The 
absence of the α-granules is observed only in individuals with biallelic variants of 
NBEAL2, as none of the patients with mild α-granule defect had pathogenic 
alterations of the gene (49). 
NBEAL2 localizes to the dense tubular system and endoplasmic reticulum, where it is 
likely to function in vesicle trafficking and membrane dynamics (47). However, why 
loss-of-function variants cause GPS is unclear, though animal models have been 
elucidating some aspects. Nbeal2-/- knockout mice recapitulate the characteristics of 
GPS with platelet defects, splenomegaly and myelofibrosis (50-52). Whereas Nbeal2 
is required for sorting and packing molecules into α-granules, it is not essential for 
generating the α-granule membranes. It also plays a role in megakaryopoiesis, as 
maturation of the Nbeal2-/- Mks is delayed with decreased ploidy and survival (51). 
These cells produce mature α-granules, suggesting that lack of Neabl2 does not 
impair α-granule formation. However, they do not retain the organelles (52). Indeed, 
α-granules release proteins that participate in hemostasis and thrombus formation, as 
well as in wound healing and inflammation (50). A link between Nebeal2 deficiency 
and myelofibrosis derives from finding that Nbeal2-/- Mks have a strong pro-
inflammatory transcriptome signature (52). Therefore, the Nbeal2-/- mouse is a 
promising model to dissect not only the function of the gene in α-granules but also 
the biological role of α-granules. 
 
Defective proplatelet formation and platelet release 
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The largest group of ITs is not associated with immature MKs but with defects of 
proplatelet formation and platelet release. This process involves dynamic 
reorganization of the cytoskeleton, signaling pathways, and apoptosis, aspects that are 
defective in various forms of ITs. In addition to impaired formation of proplatelets, 
thrombocytopenia might be related to increased clearance of platelets from circulation 
as it occurs in Wiskott-Aldrich syndrome. 
 
Defective cytoskeleton components 
MYH9-related disease (MYH9-RD) is an autosomal dominant disorder caused by 
variants of MYH9, the gene encoding for the heavy chain of non-muscle myosin IIA 
(NMMHC-IIA) (53). NMMHC-IIA is expressed in most non-muscle cells, where it 
participates in several processes requiring chemomechanical forces. It consists of 
distinct domains, at the N-terminal a globular head domain followed by a coiled coil 
domain, and a non-helical tail at the C-terminus. Like the other conventional myosins, 
NMMHC-IIA dimerizes and associates with two pairs of regulatory and essential light 
chains. MYH9-RD is characterized by thrombocytopenia with giant platelets and 
typical inclusions in the cytoplasm of granulocytes. The majority of MYH9-RD 
patients develop, as late onset, extra-hematological manifestations, sensorineural 
hearing loss, presenile cataract, proteinuric nephropathy, and chronic or intermittent 
elevation of liver enzymes (54). 
Of note is the spectrum of the MYH9 variants, mainly consisting of amino acid 
substitutions at a few of the NMMHC-IIA residues (53). Others are in-frame deletions 
or duplications in exon 24 or frame-shift and nonsense variants in the non-helical tail 
(exon 40). Variants at residues S96 and R702 in the globular head, R1165, D1424, 
and E1841 in the coiled coil domain, and R1933 in the non-helical tail account for 
almost 80% of the affected individuals. Considering that variants are detected in 
different populations and are often de novo events (>30%), it is plausible that only 
specific alterations of MYH9 are responsible for the disease. 
Genotype-phenotype studies demonstrate strong correlations. In general, alterations of 
the head domain are associated with the most severe phenotype characterized by low 
platelet number and early onset of extra-hematological features, whereas variants of 
the tail domain segregate with low risk for extra-hematological features (55). When 
these studies were extended to large cases series, the correlations were supported even 
with single variants, such as those affecting residue R702 that are strongly associated 
with early-onset end-stage renal disease and deafness or p.D1424H, whose carriers 
are at high risk of developing all the manifestations (56). By contrast, patients with 
p.E1841K, p.D1424N or C-terminal null variants have no or very low risk. All the 
MYH9 variants cause MYH9-RD, though with variable expressivity. This is true even 
for p.R705H, an amino acid substitution that was specifically associated with an 
autosomal dominant non-syndromic form of sensorineural hearing loss DFNA17. 
Only recently has it been reported that the p.R705H individuals have not only 
deafness but also the hematological defects and elevation of liver enzymes typical of 
MYH9-RD (57). 
Considering the pathophysiological aspects, the Myh9+/- mice do not have any 
alteration whereas the Myh9-/- double mutants are lethal early during embryogenesis 
(58, 59). As human MYH9-RD, conditional animals have thrombocytopenia, large 
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platelets, and an increased bleeding time (60). Reproducing the same molecular 
conditions as in patients, mice heterozygous for most frequent variants (p.R702C, 
p.D1424N, and p.E1841K) recapitulate the hematological, eye, and kidney 
manifestations (61). Not only mouse and human MYH9 mutants but also 
pharmacological inhibition of NMMHC-IIA increase proplatelet formation (62), an 
apparent paradox considering that variants are associated with thrombocytopenia. 
However, the MYH9-RD defect is likely to rely on lack of NMMHC-IIA reactivation 
in terminal platelet processing. Proplatelets are projected into microcirculation where 
shear facilitates proplatelet detachment. Fluid stress activates NMMHC-IIA, which 
accumulates at the stressed sites to induce fragmentation of preplatelets into normal 
sized platelets. If inhibited or mutated, NMMHC-IIA is diffuse and does not allow 
proplatelets to divide into small platelets, thus leading to large platelets in reduced 
number (63). 
Myosins interact with actin filaments generating contractile forces. The long actin 
filaments (F-actin) are constituted of globular actin monomers (G-actin) that 
dynamically attach and detach at the ends of the filaments. The actin polymerization 
and depolymerization processes are promoted by nucleation factors, such as the 
Wiskott-Aldrich syndrome protein (WASp), which is selectively expressed in 
hematopoietic cells (64). It exists in a close auto-inhibited form characterized by 
interaction of the C-terminus (VCA domain) with other central domains, a structure 
that is stabilized by the WASP-interacting protein (WIP) binding to the N-terminus. 
Upon activation, WASp assumes an open conformation; the VCA domain binds a G-
actin monomer, which is transferred to the Arp2/3 complex and added to F-actin. 
Therefore, alterations of the VCA domain result in complete loss of the WASp-
mediated actin polymerization. 
Variants of the WAS gene are responsible for WAS (OMIM 301000) and X-linked 
thrombocytopenia (XLT; OMIM 313900), as well as a rare form of neutropenia with 
associated myelodysplastic syndromes (65, 66). In the WAS and XLT diseases, males 
have moderate to severe thrombocytopenia with small platelets. The WAS individuals 
also have a severe immune dysregulation with susceptibility to infections and eczema 
(67-69). A wide spectrum of different WAS alleles have been described with strong 
correlations between genotype and phenotype. Loss-of-function variants, such as 
nonsense and frameshift disrupting the VCA domain, are associated with the severe 
WAS phenotype. There are, instead, amino acid substitutions mainly affecting the 
WIP interacting domain that allow expression, even at reduced levels, of normal-sized 
hypomorphic WASp and are associated with XLT. Consistent with mouse models 
(70), thrombocytopenia is due not only to inefficient platelet release into the blood 
stream but also to increased clearance of platelets from circulation. Although patients’ 
Mks are normal in number and proplatelet extension, they release platelets 
prematurely in the bone marrow. Moreover, morphologically defective platelets are 
likely to be phagocytized by the bone marrow or spleen macrophages, as splenectomy 
improves the count and quality of patients’ platelets. For mechanisms explaining the 
other phenotypic aspects of this relatively well-known IT, the interested reader is 
referred to the literature (64). 
Actin filaments are linked to α-actinin, a cytoskeleton protein organized in an actin-
binding domain (ABD), four spectrin repeats and a calmodulin-like domain (CaM). 
Antiparallel molecules dimerize in rod-like structures with ABD at each extremity for 
cross-linking the actin filaments into bundles. Among the four known isoforms, 
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ACTN1 and, to a lesser extent, ACTN4 are expressed in Mks and platelets. Variants 
of ACTN1 cause the ACTN1-related thrombocytopenia (ACTN1-RT; OMIM 615193), 
a mild form of IT without any apparent associated features (71, 72). It is worth noting 
that all the 13 different pathogenic variants identified so far are amino acid 
substitutions residing within the N- and C-terminal functional domains. Exogenous 
expression of the mutant proteins prevents actin from assembling into filaments, 
suggesting a dominant negative effect of the ACTN1 variants. Moreover, patients’ 
Mks extend proplatelets at a normal rate but their tips are reduced in number and 
increased in size, suggesting a defect in the late phase of proplatelet formation (71). 
Other actin-binding proteins are filamins, dimers connecting the actin filaments to the 
cellular membrane. In platelets, the most abundant isoform is filamin A, which is 
encoded by FLNA, a gene located on chromosome X. It has an ABD at the N-
terminus, 24 Ig-like repeats, and a dimerization domain at the C-terminus. Variants of 
FLNA determine a wide spectrum of rare brain, heart and muscle developmental 
diseases, including periventricular nodular heterotopia. The periventricular nodular 
heterotopia has sometimes been associated with thrombocytopenia, as reported in 
three females heterozygous for loss-of-function variants of FLNA (73). Consistent 
with a role of FLNA in platelet biogenesis, a novel missense variant was identified in 
an isolated thrombocytopenia (74). Moreover, a recent study showed that individuals 
with FLNA variants have defective platelet aggregation and secretion (75). Together 
with macrothrombocytopenia, similar alterations were observed in conditional mice, 
further supporting the role of FLNA in platelet production and function (76). 
FLNA, as well GPIbβ (see below), is one of the cAMP-dependent protein kinase A 
substrates. This kinase, which consists of two regulatory and two catalytic subunits, 
phosphorylates FLNA at S2152 protecting it from proteolysis (77). The gene 
encoding for the γ-isoform of the catalytic subunit, PRKACG, is mutated in an 
autosomal recessive form of macrothrombocytopenia. The only known variant 
(p.I74M) has been identified in one consanguineous family without any other features 
associated except for platelet dysfunction due to defective aggregation (78). In 
patients’ Mks and platelets, whereas the GPIbβ phosphorylation status is in the 
normal range, FLNA is expressed at low levels, suggesting a rapid degradation of the 
protein. Moreover, the percentage of proplatelet-bearing Mks is significantly reduced 
in affected individuals, a defect that can be complemented by overexpression of the 
wild-type gene, further supporting the role of PRKACG in platelet biogenesis (78). 
Other principal components of the cytoskeleton are microtubules, dynamic structures 
that, by undergoing continuous assembly and disassembly, drive a variety of cellular 
functions, such as proplatelet formation and elongation. They are heterodimers of α- 
and β-tubulin subunits. TUBB1, the gene encoding for the β1 isoform, is responsible 
for the TUBB1-related thrombocytopenia (TUBB1-RT; OMIM 613112) (79, 80). 
Since the two TUBB1 variants identified so far are located at or near the intradimer 
interface, it is likely that the mutant forms interfere with the microtubule assembly. 
TUBB1 is exclusively expressed in Mks and platelets, suggesting that TUBB1 
functions in late stages of megakaryopoiesis (81). Consistent with data on patients’ 
peripheral blood derived-Mks, overexpression of mutant forms do not allow 
microtubules to assemble and cells generate few proplatelets with large tips. Similar 
defects have been observed in mouse and dog models (82, 83), further supporting the 
hypothesis that TUBB1-RT is due to microtubule disorganization. 
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Defects in signaling pathways 
As mentioned, FLNA anchors the actin filaments to membrane glycoproteins, 
providing potential transduction of signals to the cytoskeleton network. Indeed, FLNA 
interacts with the cytoplasmic domain of GPIbα,  one of the subunits of the receptor 
(GPIb-IX-V) for the von Willebrand factor (VWF) (84). In addition to GPIbα, the 
GPIb-IX-V complex consists of another three subunits, GPIbβ, GPIX and GPV, that 
associate in the ratio 2:4:2:1 in the endoplasmic reticulum before localizing at the cell 
surface (85, 86). Variants of the GP1BA, GP1BB, and GP9 genes encoding for the 
GPIbα, GPIbβ, and GPIX subunits, respectively, cause Bernard-Soulier syndrome 
(BSS; OMIM 231200). There is a wide spectrum of variants that prevent the complex 
from associating and migrating to the platelet membrane or more rarely from 
interacting with VWF (87). As a consequence, platelets are unable to adhere to the 
vascular subendothelium and aggregate, leading to severe bleeding tendency. In 
addition to functional defects, BSS platelets are reduced in number and bigger than 
red cells.  
Although BSS is an autosomal recessive disease, monoallelic variants of GP1BA and 
GP1BB are associated with mild macrothrombocytopenia transmitted as a dominant 
trait (OMIN 153670) (87). At least in Italy, there is a significant contribution of 
p.A172V because of a founder effect (88). For a comprehensive description of ITs, it 
is worth mentioning platelet-type von Willebrand disease, a macrothrombocytopenia 
due to GP1BA variants that increase the affinity of GPIbα for VWF (87). 
Paradoxically, both a lack and excess of GPIbα stimulation produce the same effects 
on platelet biogenesis. Therefore, the interaction between VWF and GPIbα has to be 
finely modulated to guarantee the activation of specific signaling pathways through 
the interaction of the GPIb-IX-V receptor with the cytoskeleton network. Consistent 
with this hypothesis, proplatelet formation is significantly reduced from Mks of BSS 
individuals (89), though further studies are required to unravel the origin of 
thrombocytopenia.  
Another important complex of hemostasis is GPIIb-IIIa. When active, it exposes the 
binding site for fibrinogen, resulting in platelet aggregation. Biallelic variants of 
ITGA2B and ITGB3, the genes encoding for the GPIIb and GPIIIa integrin subunits of 
the receptor, cause Glanzmann thrombasthenia, an autosomal recessive bleeding 
disorder with normal platelet count. There are, however, gain-of-function variants 
affecting the GPIIb and GPIIIa regions proximal to the membrane that lead to a 
constitutive activation of the receptor (90-94). Individuals with these variants have an 
autosomal dominant macrothrombocytopenia without aggregation defects, suggesting 
that the GPIIb-IIIa receptor has to properly interact with the fibrinogen of the 
extracellular matrix of the bone marrow for platelet biogenesis (91, 95). 
 
Defects of apoptosis 
The intrinsic apoptotic pathway residing on release of cytochrome c (CYCS) from 
mitochondria is essential for proplatelet formation (5). Indeed, two variants (p.G42S 
and p.Y49H) of the CYCS gene are associated with CYCS-related thrombocytopenia 
(CYCS-RT or THC4; OMIM 612004) (96, 97). In vitro studies support the hypothesis 
that the mutant proteins determine reduction of respiration and higher apoptotic rate, 
favoring at least for the p.G42S mutant the interaction with apoptotic protease-
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activating factor 1 and consequent caspase activation (96). Dysregulation of 
megakaryopoiesis is consistent with naked Mk nuclei and platelets observed in the 
bone marrow and premature in vitro production of platelets from hematopoietic stem 
cells. This data supports the hypothesis that the intrinsic apoptotic signaling pathway 
is finely modulated during the platelet formation process.  
 
Conclusions 
ITs are relatively rare diseases not always recognized as inherited forms leading to 
misdiagnosis of affected individuals as having immune thrombocytopenia. 
Considering that clinical and hematological features are often similar among the 
different ITs and that almost 50% of families have yet uncharacterized forms of IT (1, 
98), their diagnosis is a complex process requiring a multistep approach. The review 
is limited to the genetic and pathophysiological aspects of ITs and, for a more 
comprehensive review of clinical and diagnostic aspects, the interested reader is 
referred to a paper by Pecci (2015) published in Clinical Genetics. 
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Figure legend 
 
Fig. 1. Schematic representation of megakaryopoiesis and platelet release. The 
cartoon represents the different phases of plateletet biogenesis, including 
differentiation and maturation of megakaryocytes, proplatelet production and platelet 
release into blood stream. In ITs, each phase could be affected by variants of genes 
that are also indicated. 
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